The prognostic relevance of p16 inactivation in head and neck cancer

ORL

Volumn 69, Issue 1, 2006, Pages 30-36

  Koscielny, Sven ^a   Dahse, Regine ^a,b   Ernst, Günther ^a   Von Eggeling, Ferdinand ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b HELIOS KLINIKUM ERFURT   (Germany)

Author keywords

Head and neck cancer, tumor prognosis; Inactivation of p16; Loss of heterozygosity; Methylation of promoter region

Indexed keywords

PROTEIN P16;

ARTICLE; CANCER RECURRENCE; CARCINOGENESIS; FOLLOW UP; GENE INACTIVATION; GENETIC CORRELATION; HEAD AND NECK CANCER; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; LARYNX; MAJOR CLINICAL STUDY; METHYLATION; MOUTH CAVITY; PHARYNX; POINT MUTATION; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

CARCINOMA, SQUAMOUS CELL; DNA METHYLATION; GENE SILENCING; GENES, P16; HUMANS; LOSS OF HETEROZYGOSITY; OTORHINOLARYNGOLOGIC NEOPLASMS; POINT MUTATION; PROGNOSIS; PROMOTER REGIONS (GENETICS); SURVIVAL RATE;

EID: 33845797028     PISSN: 03011569     EISSN: None     Source Type: Journal    
DOI: 10.1159/000096714     Document Type: Article

References (49)

1. Serrano M, Hannon GJ, Beach D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993;366:704-707.
2. Lundblad V: The end replication problem: more than one solution. Nat Med 1997;3:1189-1198.
3. Luca M, Xie S, Gutman M, Huang S, Bar-Eli M: Abnormalities in the CDKN 2 (p16 INK4/MTS-1) gene in human melanoma cells: relevance to tumor growth and metastasis. Oncogene 1995;11:1399-1402.
4. Serrano M: The tumor suppressor protein p16INK4a. Exp Cell Res 1997;237:7-13.
5. Lilischikis R, Sabcevic B, Kennedy C, Walters A, Sutherland RL: Cancer-associated missense and deletion mutations impair p16 INK4 CDK inhibitory activity. Int J Cancer 1996;65:249-254.
6. Reed JA, Loganzo F, Shea CR, Walker GJ, Flores JF, Glendning JM, et al: Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. Cancer Res 1995;55:2713-2718.
7. Loughran O, Edington KD, Berry IJL, Clark J, Parkinson LJ: Loss of heterozygosity of chromosome 9p21 is associated with the immortal phenotype of neoplastic human head and neck keratinocytes. Cancer Res 1994;54:5045-5049.
8. 1 arrest: molecular mechanisms and implications for oncogenesis. Oncogene 1999;18:3930-3935.
9. Riese U, Dahse R, Fiedler W, Koscielny S, Theuer C, Ernst G, et al: Tumor suppressor gene p16 (CDKN2A) mutation status and promoter inactivation in head and neck cancer. Int J Mol Med 1999;4:61-65.
10. Huang L, Goodrow L, Zhang SY, Klein-Szanto AJP, Chang H, Ruggert BA: Deletion and mutation analyses of the p16/MTS 1 tumor suppressor gene in human ductal pancreatic cancer reveals a higher frequency of abnormalities in tumor-derived cell lines than in primary ductal adenocarcinomas. Cancer Res 1996;56:1137-1141.
11. Riet P, Nawroz H, Hruban RH, Tokino K, Koch W, Sidransky D: Frequent loss of chromosome 9p21-22 early in the head and neck cancer progression. Cancer Res 1994;54:1156-1158.
12. Shapiro GI, Edwards CD, Kobzik L, Godleski J, Richards W, Sugarbaker DJ, et al: Reciprocal Rb inactivation and p16 INK4 expression in primary lung cancers and cell lines. Cancer Res 1995;55:505-509.
13. Gonzalez MV, Pello MF, Lopez-Larrea C, Suarez C, Menendez MJ, Coto E: Deletion and methylation of the tumour suppressor gene p16/CDKN2 in primary head and neck squamous cell carcinoma. J Clin Pathol 1997;50:509-512.
14. Maelandsmo GM, Florenes VA, Hovig E, Oyjord T, Engelbraaten O, Holm R, et al: Involvement of the pRb/p16/cdk4/cyclin D1 pathway in the tumorigenesis of sporadic melanomas. Br J Cancer 1996;73:909-916.
15. Cairns P, Li M, Merlo A, Lee DJ, Schwab D, Eby Y, et al: Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science 1994;265:415-416.
16. Kamb A, Liu Q, Harshman K, Tatigion S, Cordon-Cardo C, Skolnick MH: Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science 1999;265:415-417.
17. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, et al: 5′-CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/cdkn2/mts1 in human cancers. Nat Med 1995;1:686-692.
18. Mutirangura A, Supiyaphun P, Trirekapan S, Sriuranpong V, Sakuntabhai A, Yenrudi S, et al: Telomerase activity in oral leukoplakia and head and neck squamous cell carcinoma. Cancer Res 1996;56:3530-3533.
19. Zhang Y, Xiong Y, Yarbrough WG: ARF promotes MDM 2 degradation and stabilises p53: ARF-INK 4A locus deletion impairs both the Rb and p53 tumor suppression pathway. Cell 1998;92:725-734.
20. Cody DT, Huang Y, Darby CJ, Johnson GK, Domann FE: Differential DNA methylation of the p16 INK4A/CDKN2A promoter in human oral cancer cells and normal human oral keratinocytes. Oral Oncol 1999;35:516-522.
21. El-Naggar AK, Lai S, Clayman G, Lee JK, Luna MA, Goepfert H, et al: Methylation, a major mechanism of p16/CDKN2 gene inactivation in head and neck squamous carcinoma. Am J Pathol 1997;151:1767-1774.
22. Miracca EC, Kowalski LP, Nagai MA: High prevalence of p16 genetic alterations in head and neck tumours. Br J Cancer 1999;81:677-683.
23. Rusin MR, Okamoto A, Chorazy K, Czyzewski K, Harasim J, Spilare EA, et al: Intragenic mutations of the p16 INK 4, p15 INK 4 B and p18 genes in primary non-small-cell lung cancers. Int J Cancer 1996;65:734-739.
24. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, et al: 5′-CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/cdkn2/mts1 in human cancers. Nat Med 1995;1:686-692.
25. Gonzalez MV, Pello MF, Lopez-Larrea C, Suarez C, Menendez MJ, Coto E: Deletion and methylation of the tumour suppressor gene p16/CDKN2 in primary head and neck squamous cell carcinoma. J Clin Pathol 1997;50:509-512.
26. Bova RJ, Quinn DI, Nankervis JS, Cole IE, Sheridan BF, Jensen M, et al: Cyclin D1 and p16INK4A expression predict reduced survival in carcinoma of the anterior tongue. Clin Cancer Res 1999;5:2810-2819.
27. Danahey DG, Tobin EJ, Schuller DE, Bier-Laning CM, Weghorst CM, Lang JC: p16 mutation frequency and clinical correlation in head and neck cancer. Acta Otolaryngol 1999;119:285-288.
28. Koscielny S, Fiedler W, Beleites E, Claussen U: Welche Rolle spielt die Inaktivierung des Promotors p16 bei der Entstehung eines Kopf-Hals-Karzinoms? HNO 1999;47:396.
29. Lagoda PJ, Seitz G, Eppelen JT, Issinger OG: Increased detectability of somatic changes in the DNA from human tumours after probing with 'synthetic' and 'genome-derived' hypervariable multilocus probes. Hum Genet 1989;84:35-40.
30. Danahey DG, Tobin EJ, Schuller DE, Bier-Laning CM, Weghorst CM, Lang JC: p16 mutation frequency and clinical correlation in head and neck cancer. Acta Otolaryngol 1999;119:285-288.
31. Dai S, Huang W, Gan X: The expression of p16, Rb and Cyclin D1 and biological behaviour of laryngeal cancer. Chung Hua Erh Pi Yen Hou Ko Tsa Chih 1997;32:299-301.
32. Gulley ML, Nicholls JM, Schneider BG, Amin MB, Ro JY, Geradts J: Nasopharyngeal carcinomas frequently lack the p16/MTS1 tumor suppressor protein but consistently express the retinoblastoma gene product. Am J Pathol 1998;152:865-869.
33. Shibosawa E, Tsutsumi K, Koizuka I, Hoshikawa M, Takakuwa T: Absence of nuclear p16 from Epstein-Barr virus-associated undifferentiated nasopharyngeal carcinomas. Laryngoscope 2000;110:93-97.
34. Zhao Y, Zhang S, Fu B, Xiao C: Abnormalities of tumor suppressor genes P16 and P15 in primary maxillofacial squamous cell carcinomas. Cancer Genet Cytogenet 1999;112:26-33.
35. Sato K, Schäuble B, Kleihues P, Ogaki H. Infrequent alterations of the p15, p16, CDK 4 and cyclin D1 genes in non-astrocytic human brain tumors. Int J Cancer 1998;65:305-308.
36. Musgrove EA, Lilischkis R, Cornish AL, Lee CSL, Setlur V, Seshadri R, et al: Expression of the cyclin-dependent kinase inhibitors p16 INK4, p15 INK4B and p21 WAF1/CIPI in human breast cancer. Int J Cancer 1995;63:584-591.
37. Faderl S, Estrov Z, Kantarjian HM, Thomas D, Cortes J, Manshouri T, et al: The incidence of chromosome 9p21 abnormalities and deletions of tumor suppressor genes p15(INK4b)/p16(INK4a)/p14(ARF) in patients with acute lymphoblastic leukaemia. Cytokines Cell Mol Ther 1999;5:159-163.
38. Guo SX, Taki T, Ohnishi H, Piao HY, Tabuchi K, Bessho F, et al: Hypermethylation of p16 and p15 genes and RB protein expression in acute leukaemia. Leuk Res 2000;24:39-46.
39. Woodcock DM, Linsenmeyer ME, Doherty JP, Warren WD: DNA methylation in the promoter region of the p16 (CDKN2/MTS-1/INK4A) gene in human breast tumours. Br J Cancer 1999;79:251-256.
40. Jares P, Nadal A, Fernandez PL, Pinyol M, Hernandez L, Cazorla M, et al: Disregulation of p16MTS1/CDK4I protein and mRNA expression is associated with gene alterations in squamous-cell carcinoma of the larynx. Int J Cancer 1999;81:705-711.
41. Maelandsmo GM, Florenes VA, Hovig E, Oyjord T, Engelbraaten O, Holm R, et al: Involvement of the pRb/p16/cdk4/Cyclin D1 pathway in the tumorgenesis of sporadic melanomas. Br J Cancer 1996;73:909-916.
42. Kyritsis AP, Zhang B, Zhang W, Xio M, Takeshima H, Bondy ML, et al.: Mutations of the p16 gene in gliomas. Oncogen 1995;11:63-67.
43. Sato K, Schäuble B, Kleihues P, Ogaki H: Infrequent alterations of the p15, p16, CDK 4 and cyclin D1 genes in non-astrocytic human brain tumors. Int J Cancer 1996;65:305-308.
44. Kelly MJ, Otterson GA, Kaye FJ, Popescu NC, Johnson BE, Dipaolo JA: CDKN 2 in HPV-positive and HPV-negative cervical carcinoma cell lines. Int J Cancer 1995;63:226-230.
45. Yeudall WA, Crawford RY, Ensley JF, Robbins KC: MTS 1/CDK41 is altered in cell lines derived from primary and metastatic oral squamous cell carcinoma. Carcinogenesis 1994;15:2683-2686.
46. Mori T, Miura K, Aoki K, Nishihira A, Mori S, Nakamura Y: Frequent somatic mutation of the MTS1/CDK 41 gene in esophageal squamous cell carcinoma. Cancer Res 1994;54:3396-3397.
47. Skollnick MH, Cannon-Albright LA, Kamb A: Genetic predisposition to melanoma. Eur J Cancer 1994;30:1991-1995.
48. Yuan J, Knorr J, Altmannsberger M, Goeckenjan G, Ahr A, Scharl A, et al: Expression of p16 and lack of pRB in primary small cell lung cancer. J Pathol 1999;189:358-362.
49. Takeuchi H, Ozawa S, Ando N, Shih CH, Koyanagi K, Ueda M, et al: Altered p16/MTS1/CDKN2 and cyclin D1/PRAD-1 gene expression is associated with the prognosis of squamous cell carcinoma of the esophagus. Clin Cancer Res 1997;3:2229-2236.